Akzo Nobel Pharma and Base Ten Systems Sign Global Purchase Agreement for Implementation of BASE10 Manufacturing Execution Systems At Akzo Nobel's Pharmaceutical Manufacturing Sites.

OSS, The Netherlands and TRENTON, N.J.--(BW HealthWire)--June 15, 1999--

-- Discussions Under Way to Implement BASE10(tm) MES at

Akzo Nobel's Worldwide Pharmaceutical Manufacturing Sites --

NV Organon, and Diosynth B.V., business units of Akzo Nobel N.V. (Nasdaq:AKZOY)(Amsterdam Stock Exchange:AKZO), of Arnhem, the Netherlands, and Base Ten Systems, Inc. (Nasdaq:BASEA), of Trenton, New Jersey, today announced that they have signed a global purchase agreement under which Base Ten will implement its BASE10(tm) Manufacturing Execution Systems ("BASE10(tm)MES") at worldwide manufacturing and clinical manufacturing sites of NV Organon and Diosynth B.V.

The manufacturing sites where BASE10(tm)MES will initially be implemented will be announced shortly.

Dr. J. Lakeman, Managing Director, NV Organon and Ir. A. Sanders, Managing Director Diosynth B.V., said: "We are pleased to have signed this agreement. After a thorough selection process we have chosen BASE10(tm)MES to support our manufacturing process, as a part of Akzo Nobel's strategy to apply state-of-the-art information technology. We are confident that the BASE10(tm)MES system will contribute to that goal."

Thomas E. Gardner, chairman and chief executive officer of Base Ten Systems, said: "This global purchase agreement with Akzo Nobel's pharmaceutical business units is a major vote of confidence in Base Ten Systems and in the ability of our flagship BASE10(tm)MES technology to enable a world-class pharmaceutical company to enjoy more cost-effective regulatory compliance, improve its manufacturing flexibility and reduce its production cycle. As the designated supplier of manufacturing execution systems to Akzo Nobel's pharmaceutical business units that implement such technology, Base Ten gains a major strategic partner, a broad global presence and a major validation of our core technology. We are delighted to team up with this outstanding company and look forward to a long and mutually beneficial relationship."

NV Organon and Diosynth B.V. are pharmaceutical business units of Akzo Nobel. Akzo Nobel, based in the Netherlands, serves customers throughout the world with healthcare products, coatings, chemicals, and fibers. The fibers business, now known as Acordis, will be demerged. The company currently employs approximately 86,000 people and has activities in more than 70 countries.

As of 1999, the Euro will be Akzo Nobel's external reporting currency. Consolidated sales for 1998 totaled $13.8 billion (NLG 27.5 billion / EUR 12.5 billion / GBP 8.4 billion). Financial results for the second quarter of 1999 will be announced on July 28.

In North America, more than 9,000 people in over 150 locations work for the company, which has U.S. headquarters in Chicago. Akzo Nobel's American Depositary Receipts (ADRs) are traded on NASDAQ under the AKZOY symbol. Internet: www.akzonobel.com.

Base Ten Systems is a software technology development company focused on manufacturing execution systems and services for the pharmaceutical, chemicals and medical products industries. Through installation of BASE10(tm) software, the company's customers around the world can enjoy more cost-effective regulatory compliance, improved manufacturing flexibility and reduced production cycle time.

BASE10(tm) execution systems are readily integrated with complementary software partners as manufacturers consolidate their operations into global supply chain processes. Learn more about Base Ten Systems by visiting its web site at www.base10.com.

Forward-Looking Statements Regarding Base Ten Systems

The foregoing contains "forward-looking information" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by the letter ("a") or by such forward-looking terminology as "may," "will," "believe," "anticipate," "expect," or similar words or variations thereof.

Such forward-looking statements involve certain significant risks and uncertainties. Important factors that the Company believes may cause actual results to differ materially from such forward-looking statements are discussed in the "Risk Factors," "Business" and "MD&A" sections of the Company's current S-3 registration statements and annual and quarterly reports on file with the Securities and Exchange Commission.

Additional risk factors include the effectiveness of software and the ability of software to operate without "bugs" in the technology and acceptance of the release by customers and actual rollout. In assessing such forward-looking statements, investors are urged to read carefully those reports and other filings.

The Company does not undertake to publicly update or revise its forward-looking statements, even if experience or future changes indicate that any such results or event (expressed or implied) will not be realized.